In-Training - Arrhythmias Flashcards
Which patients are ICD placement in HCM recommended (secondary prevention)?
- prior documented cardiac arrest
- VF
- VT (hemodynamically significant)
What is an abnormal BP response to exercise?
failure to increase SBP by 20 mmHg
or
drop of 20 mmHg during effort
What is the mechanism of death in HCM?
VT emanating from an abnormal myocardial substrate consiting of myocyte disarray and interstitial and replacment fibrosis
What are the five primary risk factors (indications for ICD - primary prevention) for SCD in HCM?
- FH of premature HCM-related death
- particularly if sudden death, and in close or multiple relatives
- Syncope (unexplained)
- determined to be non-neurocardiogenic
- particularly if recent, in young patients
- NSVT on serial ambulatory ECG’s
- particularly when bursts are multiple, repetitive, or prolonged
- Hypotensive or attenuated BP response to exercise
- LV hypertrophy (LV wall thickness >30mm)
- Extensive LGE ( > 15% of LV mass) on CMR
- twofold risk compared with no LGE
- Double or compound genetic mutations
What is a key determinant influencing SCD in HCM patients?
- Age
- noninvasive risk markers are most applicable to young and middle-aged HCM patients
- achievement of advanced age ( > 60 years) is associated with low risk, even in the presence of conventional risk factors
What are additional risk factors/subgroups (other than 5 primary) that may contribute to risk stratificaiton of HCM patients?
- LGE ( >15% of LV mass) on CMR
- LV apical aneurysm
- LVEF < 50%
- “end stage” systolic dysfunction
What is the next best step in a HCM patient:
- no FH
- asymptomatic (no syncope)
- LVOT gradient 40mmHg
- Normal BP response to exercise
ECG (ambulatory) monitoring
- continued evaluation for NSVT/VT for primary prevention
What is the best treatment option for:
- supine hypertension
- orthostatic symptomatic hypotension
- Droxidopa
- indicated for neurogenic orthostatic hypotension
- MOA: induces peripheral arterial/venous vasoconstriction
- class = inotropes/pressors
- Other options: pyridostigmine, midodrine, fludrocortisone
- drugs may exacerbate hypertension
- Lifestyle modifications:
- put head of bed up about 30 degrees to offset the supine and evening hypertension when there is often fluid retention
- avoid eating very sweet carbohydrate-laden foods in the morning
Dual chamber PPM (for SND and 3rd degree heart block) presents with palpitations. What is the best way to decrease his symptoms?
Beta-blocker therapy (Metoprolol) 25mg BID
What is the diagnosis?
Treatment?
- Vasovagal syncope
- Mixed vasodepressor and cardio-inhibitory vagal response
- Patient reassurance and education, emphasizing fluid and salt intake, physical counterpressure maneuvers
What is the best medication for maintenance of sinus rhythm after DCCV for Atrial fibrillation?
- decompensated CHF (JVP 16 cm H2O, dullness over right lung base, obese abdomen with palpable liver edge, warm extremities + trace edema)
- EKG: rapid A-fib with LBBB
- Echo: EF 35%, end-diastolic dimension 60mm
- GFR = 30cc/min
Amiodarone –> restoration of NSR may improve HF (if tachycardia induced)
- Sotalol, Dofetilide contraindicated 2/2 renal failure
- Flecainide (class Ic agents) contraindicated in HF
- Dronedarone contraindicated in NYHA IV or II-III with recent decompensation requiring hospitalization and permanent A-fib
What are the major side effects of Ticagrelor?
- dyspnea (15% of patients within the first week of treatment)
- bradycardia
- bleeding
What is the MOA of ticagrelor?
What trial compared ticagrelor and clopidogrel?
What were the results?
- P2Y12 inhibitor –> reversibly binding, direct-acting agent
- PLATO trial
- ticagrelor was associated with lower:
- death
- stroke
- stent thrombosis
- higher risk of bleeding (CABG-related bleeding)
What medication can lead to decreased effectiveness of ticagrelor?
high-dose ASA
How long does BB therapy provide a mortality benefit in patients with CAD?
3 years (hasn’t been studies longer)